Martine A. Rothblatt, serving as both Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ:UTHR), has officially reported the sale of 9,500 shares of common stock. The transaction, valued at a total of $5,212,519, was executed on June 24, 2026. The shares were divested at prices fluctuating between $545.9257 and $553.2448 per share. This activity occurs as the company's stock trades at $543.39, a level near its 52-week high of $609.35, following a substantial 92% appreciation over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, positioning it among the most overvalued equities in the market.
The recent sale was preceded by the acquisition of an identical quantity of 9,500 shares. These shares were obtained through the exercise of stock options at a price of $135.42 per share, resulting in a total value of $1,286,489. All transactions, encompassing both the option exercises and the subsequent sale of common stock, were conducted under a pre-arranged 10b5-1 trading plan. This plan was established by Ms. Rothblatt on November 7, 2025, and is scheduled to remain active until the earlier of two conditions: the exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026.
Following these transactions, Ms. Rothblatt's direct holdings in United Therapeutics common stock stand at 40,513 shares. Her indirect holdings include 166 shares held by her spouse. Additionally, she maintains interests in various family trusts: 324,443 shares in trusts where she shares investment power and where she and/or immediate family members are beneficiaries; 249,108 shares in trusts where her spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke; 45,596 shares in trusts where her spouse shares investment power and where she and/or immediate family members are beneficiaries; and 8,902 shares in trusts where she is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
While the CEO executed this planned sale, InvestingPro Tips reveal that management has been aggressively buying back shares, demonstrating confidence in the company’s $23.17 billion market capitalization. Investors can access 12 additional ProTips, along with comprehensive Pro Research Reports covering UTHR and 1,400+ other US equities, to gain deeper insights into the company’s financial health and valuation.
United Therapeutics recently reported its first-quarter financial results, which fell short of analyst expectations. The company announced revenue of $781.5 million, missing the consensus estimate of $797.4 million. Tyvaso revenues were $457.5 million, below the expected $478.6 million. Net income was also lower than anticipated, at $274.9 million compared to the consensus estimate of $320.5 million. Despite this, TD Cowen reiterated its Buy rating on United Therapeutics, maintaining a price target of $675.00.
In clinical developments, United Therapeutics announced that its TETON-1 phase 3 study of nebulized Tyvaso for idiopathic pulmonary fibrosis met its primary endpoint, with results published in the New England Journal of Medicine. The study showed that Tyvaso preserved lung function and reduced the risk of clinical worsening events significantly. Additionally, United Therapeutics has partnered with Varda Space Industries to explore microgravity-based pharmaceutical processing for rare pulmonary diseases.
Lastly, BTIG reiterated a Neutral rating on United Therapeutics following the first-quarter results. These developments highlight the company’s ongoing efforts in drug development and strategic partnerships.